Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark-Celon Generic Seretide DPI On Its Way In Europe

Executive Summary

Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) appears on course for a debut in Europe, piling up more pressure on GlaxoSmithKline’s respiratory franchise. Substitutability of the generic, however, will be key to driving momentum in uptake.

You may also be interested in...



Will Glenmark-Celon’s ‘Substitutable’ Seretide Deliver In Europe?

Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) has hit the Danish market but whether it can build momentum around its regulatory clearance for substitution remains to be seen.

Will Glenmark-Celon’s ‘Substitutable’ Seretide Deliver In Europe?

Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) has hit the Danish market but whether it can build momentum around its regulatory clearance for substitution remains to be seen.

Seretide Competition Builds Up But Substitutability Holds Key?

More possible competition is building for GlaxoSmithKline's blockbuster salmeterol and fluticasone combination, with a second Indian firm teaming up with the Polish biopharmaceutical company Celon to produce a version of the product.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel